AT536418T - Lipidverkapselte interference-rna - Google Patents

Lipidverkapselte interference-rna

Info

Publication number
AT536418T
AT536418T AT05757651T AT05757651T AT536418T AT 536418 T AT536418 T AT 536418T AT 05757651 T AT05757651 T AT 05757651T AT 05757651 T AT05757651 T AT 05757651T AT 536418 T AT536418 T AT 536418T
Authority
AT
Austria
Prior art keywords
lipidverkapselte
rna
interference
Prior art date
Application number
AT05757651T
Other languages
German (de)
Inventor
Ian Maclachlan
Lorne R Palmer
James Heyes
Original Assignee
Protiva Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US57807504P priority Critical
Priority to US57796104P priority
Priority to US61074604P priority
Priority to US67942705P priority
Application filed by Protiva Biotherapeutics Inc filed Critical Protiva Biotherapeutics Inc
Priority to PCT/CA2005/000886 priority patent/WO2005121348A1/en
Publication of AT536418T publication Critical patent/AT536418T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific
AT05757651T 2004-06-07 2005-06-07 Lipidverkapselte interference-rna AT536418T (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US57807504P true 2004-06-07 2004-06-07
US57796104P true 2004-06-07 2004-06-07
US61074604P true 2004-09-17 2004-09-17
US67942705P true 2005-05-09 2005-05-09
PCT/CA2005/000886 WO2005121348A1 (en) 2004-06-07 2005-06-07 Lipid encapsulated interfering rna

Publications (1)

Publication Number Publication Date
AT536418T true AT536418T (en) 2011-12-15

Family

ID=35503071

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05757651T AT536418T (en) 2004-06-07 2005-06-07 Lipidverkapselte interference-rna

Country Status (7)

Country Link
US (4) US7799565B2 (en)
EP (1) EP1766035B1 (en)
JP (1) JP4796062B2 (en)
AT (1) AT536418T (en)
AU (1) AU2005252273B2 (en)
CA (1) CA2569664C (en)
WO (1) WO2005121348A1 (en)

Families Citing this family (226)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491164C (en) 2002-06-28 2012-05-08 Cory Giesbrecht Method and apparatus for producing liposomes
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
AU2004257373B2 (en) * 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
CA2551022C (en) * 2003-09-15 2013-06-04 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
JP4937899B2 (en) 2004-03-12 2012-05-23 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
CA2572439A1 (en) 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor
JP2008509205A (en) * 2004-08-13 2008-03-27 アイシー・ベック・リミテッドIC Vec Limited Vector containing the polymer-modified siRNA liposome
GB0418172D0 (en) * 2004-08-13 2004-09-15 Ic Vec Ltd Vector
EP1799825B1 (en) 2004-10-05 2011-06-29 The California Institute of Technology Aptamer regulated nucleic acids and uses thereof
EP2199298A1 (en) * 2004-11-17 2010-06-23 Protiva Biotherapeutics Inc. Sirna silencing of Apolipoprotein B
EP1979364A4 (en) 2005-08-23 2010-10-27 Univ Pennsylvania Rna containing modified nucleosides and methods of use thereof
US20070054873A1 (en) * 2005-08-26 2007-03-08 Protiva Biotherapeutics, Inc. Glucocorticoid modulation of nucleic acid-mediated immune stimulation
US20070087045A1 (en) * 2005-10-14 2007-04-19 Industrial Technology Research Institute Lipid carrier and method of preparing the same
US7838658B2 (en) 2005-10-20 2010-11-23 Ian Maclachlan siRNA silencing of filovirus gene expression
US8101741B2 (en) 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
WO2007056861A1 (en) * 2005-11-18 2007-05-24 Protiva Biotherapeutics, Inc. Sirna silencing of influenza virus gene expression
USRE45660E1 (en) 2006-02-14 2015-09-01 Bp Corporation North America Inc. Xylanases, nucleic acids encoding them and methods for making and using them
CN101437954B (en) 2006-03-07 2015-09-09 嘉吉公司 Aldolase and nucleic acids encoding the aldolase and their preparation and use
BR122017003017B1 (en) 2006-03-07 2018-10-23 Basf Enzymes Llc nucleic acid, expression cassette, vector, cloning vehicle transgenic organism, polypeptide, signal peptide, composition, and methods for producing a recombinant polypeptide, to generate a variant of a nucleic acid to cleave a carbon-carbon bond in a composition to form a carbon-carbon bond, to a foodstuff, an animal feed or drink, and to convert a biomass or any lignocellulosic material in a fuel
KR101036126B1 (en) 2006-05-11 2011-05-23 알닐람 파마슈티칼스 인코포레이티드 Compositions and methods for inhibiting expression of the PCSK9 gene
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US8138160B2 (en) 2006-08-03 2012-03-20 Warsaw Orthopedic, Inc. Reagents, methods and systems to suppress pro-inflammatory cytokines
WO2008019486A1 (en) * 2006-08-16 2008-02-21 Protiva Biotherapeutics, Inc. Nucleic acid modulation of toll-like receptor-mediated immune stimulation
EP2057179A4 (en) * 2006-08-24 2010-11-10 British Columbia Cancer Agency Compositions and methods for treating myelosuppression
CN101616677B (en) * 2006-10-03 2015-07-22 阿尔尼拉姆医药品有限公司 Lipid containing formulations
KR100817024B1 (en) * 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 Composite for specifically transporting a nucleic acid or a drug to liver and pharmaceutical composition comprising the same
US8158595B2 (en) 2006-11-09 2012-04-17 California Institute Of Technology Modular aptamer-regulated ribozymes
KR100825519B1 (en) * 2007-01-05 2008-04-25 오유경 A chitosan based polymer conjugate and a method for producing the same
UA101156C2 (en) 2007-04-27 2013-03-11 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа Plant co2 sensors, coding nucleic acids, and methods for production and using thereof
WO2009002719A1 (en) * 2007-06-22 2008-12-31 The Board Of Regents Of The University Of Texas System Liposomal inhibitory nucleic acid against stat proteins
US20090082217A1 (en) * 2007-07-16 2009-03-26 California Institute Of Technology Selection of nucleic acid-based sensor domains within nucleic acid switch platform
CA2733676A1 (en) 2007-08-10 2009-02-19 British Columbia Cancer Agency Branch Microrna compositions and methods for the treatment of myelogenous leukemia
US20120165387A1 (en) 2007-08-28 2012-06-28 Smolke Christina D General composition framework for ligand-controlled RNA regulatory systems
US8367815B2 (en) * 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US8865667B2 (en) 2007-09-12 2014-10-21 California Institute Of Technology Higher-order cellular information processing devices
US8486680B2 (en) 2007-10-03 2013-07-16 Bp Corporation North America Inc. Xylanases, nucleic acids encoding them and methods for making and using them
WO2009052454A2 (en) 2007-10-19 2009-04-23 University Of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
RU2010123882A (en) * 2007-11-14 2011-12-20 Те Риджентс Оф Те Юниверсити Оф Калифорния (Us) Modified amphiphilic lipids, sterols
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
EP2238251B1 (en) 2007-12-27 2015-02-11 Protiva Biotherapeutics Inc. Silencing of polo-like kinase expression using interfering rna
WO2009086558A1 (en) * 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
CA2711236A1 (en) * 2008-01-02 2009-07-16 Alnylam Pharmaceuticals, Inc. Screening method for selected amino lipid-containing compositions
WO2009088753A1 (en) 2008-01-03 2009-07-16 Verenium Corporation Isomerases, nucleic acids encoding them and methods for making and using them
CA2710683A1 (en) 2008-01-03 2009-07-16 Verenium Corporation Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
MX2010008394A (en) * 2008-01-31 2010-11-12 Alnylam Pharmaceuticals Inc Optimized methods for delivery of dsrna targeting the pcsk9 gene.
EA019531B1 (en) * 2008-03-05 2014-04-30 Элнилэм Фармасьютикалз, Инк. COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
KR20100131509A (en) 2008-03-31 2010-12-15 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 Double-stranded lipid-modified rna having high rna interference effect
EP2770057A1 (en) 2008-04-15 2014-08-27 Protiva Biotherapeutics Inc. Silencing of CSN5 gene expression using interfering RNA
CA2721333A1 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
WO2009129385A1 (en) * 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof
WO2009129395A1 (en) * 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
US20110224447A1 (en) * 2008-08-18 2011-09-15 Bowman Keith A Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids
TW201019963A (en) * 2008-09-10 2010-06-01 Abbott Lab Polyethylene glycol lipid conjugates and uses thereof
WO2010030730A1 (en) * 2008-09-10 2010-03-18 Abbott Laboratories Polyethylene glycol lipid conjugates and uses thereof
JP2012502991A (en) 2008-09-22 2012-02-02 アールエックスアイ ファーマシューティカルズ コーポレーション rna interference in the skin applied
JP5529142B2 (en) 2008-09-25 2014-06-25 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. Lipid formulations compositions and methods for inhibiting the expression of serum amyloid a gene
CA2984026A1 (en) 2008-10-09 2010-04-15 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
KR20160079921A (en) 2008-10-20 2016-07-06 알닐람 파마슈티칼스 인코포레이티드 Compositions and methods for inhibiting expression of transthyretin
AU2009311667B2 (en) 2008-11-07 2016-04-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
CN105709229A (en) 2008-11-10 2016-06-29 阿尔尼拉姆医药品有限公司 Novel lipids and compositions for the delivery of therapeutics
JP5600299B2 (en) * 2008-11-26 2014-10-01 中外製薬株式会社 Vesicle preparation
EP2368989A4 (en) 2008-11-26 2012-09-26 Chugai Pharmaceutical Co Ltd Oligoribonucleotide or peptide nucleic acid capable of inhibiting activity of hepatitis c virus
CA2746514C (en) 2008-12-10 2018-11-27 Alnylam Pharmaceuticals, Inc. Gnaq targeted dsrna compositions and methods for inhibiting expression
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
CN104922699A (en) * 2009-03-12 2015-09-23 阿尔尼拉姆医药品有限公司 LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
US9145555B2 (en) 2009-04-02 2015-09-29 California Institute Of Technology Integrated—ligand-responsive microRNAs
US20100285112A1 (en) * 2009-05-05 2010-11-11 Tatiana Novobrantseva Methods of delivering oligonucleotides to immune cells
KR20120050429A (en) * 2009-06-15 2012-05-18 알닐람 파마슈티칼스 인코포레이티드 Lipid formulated dsrna targeting the pcsk9 gene
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
EP2449114B9 (en) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011000108A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein b
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011011447A1 (en) 2009-07-20 2011-01-27 Protiva Biotherapeutics, Inc. Compositions and methods for silencing ebola virus gene expression
EP2810643A3 (en) 2009-08-14 2015-03-11 Alnylam Pharmaceuticals Inc. Lipid formulated compositions and mehods for inhibiting expression of a gene from the ebola virus
WO2011038031A1 (en) 2009-09-22 2011-03-31 Alnylam Pharmaceuticals, Inc. Dual targeting sirna agents
CA2775092A1 (en) 2009-09-23 2011-03-31 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
JP5723378B2 (en) 2009-11-03 2015-05-27 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. Lipid formulation compositions and methods for inhibiting transthyretin (ttr)
EP3318248B1 (en) 2009-12-01 2019-04-10 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
AU2014250713B2 (en) * 2009-12-01 2016-07-28 Translate Bio, Inc. Delivery Of mRNA For The Augmentation Of Proteins And Enzymes In Human Genetic Diseases
AU2016250459B2 (en) * 2009-12-01 2018-06-28 Translate Bio, Inc. Delivery Of mRNA For The Augmentation Of Proteins And Enzymes In Human Genetic Diseases
EP2516010A2 (en) 2009-12-23 2012-10-31 Novartis AG Lipids, lipid compositions, and methods of using them
EP2526113B1 (en) 2010-01-22 2016-08-10 Sirna Therapeutics, Inc. Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
US9340786B2 (en) 2010-03-24 2016-05-17 Rxi Pharmaceuticals Corporation RNA interference in dermal and fibrotic indications
CN103200945B (en) 2010-03-24 2016-07-06 雷克西制药公司 rna interference in ocular symptoms
CA2794307A1 (en) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
AU2011245987B2 (en) 2010-04-28 2016-12-15 Kyowa Hakko Kirin Co., Ltd Cationic lipid
JP5902617B2 (en) 2010-04-28 2016-04-13 協和発酵キリン株式会社 Cationic lipid
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
US10077232B2 (en) 2010-05-12 2018-09-18 Arbutus Biopharma Corporation Cyclic cationic lipids and methods of use
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
MX2013000164A (en) 2010-07-06 2013-03-05 Novartis Ag Liposomes with lipids having an advantageous pka- value for rna delivery.
LT2590676T (en) 2010-07-06 2016-10-25 Glaxosmithkline Biologicals Sa Virion-like delivery particles for self-replicating rna molecules
US9801897B2 (en) 2010-07-06 2017-10-31 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
DK2591114T3 (en) 2010-07-06 2016-08-29 Glaxosmithkline Biologicals Sa Immunization of large mammals with low doses of RNA
EP2601212A1 (en) 2010-08-04 2013-06-12 Cizzle Biotechnology Limited Methods and compounds for the diagnosis and treatment of
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012027675A2 (en) 2010-08-26 2012-03-01 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
CA2809851A1 (en) 2010-08-31 2012-03-08 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
BR112013004865A2 (en) 2010-08-31 2016-06-07 Novartis Ag lipids suitable for delivery of liposomal protein-coding RNA
WO2012030901A1 (en) 2010-08-31 2012-03-08 Novartis Ag Small liposomes for delivery of immunogen-encoding rna
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
EP2857413A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
KR20140044356A (en) 2011-06-08 2014-04-14 샤이어 휴먼 지네틱 테라피즈 인크. Lipid nanoparticle compositions and methods for mrna delivery
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
CN103748078B (en) 2011-06-08 2016-11-09 夏尔人类遗传性治疗公司 Cleavable lipid
RU2014104090A (en) 2011-07-06 2015-08-20 Новартис Аг Liposomes with an effective ratio of n: p to deliver molecules phk
DK2750707T3 (en) 2011-08-31 2019-02-11 Glaxosmithkline Biologicals Sa Pegylated liposomes for the delivery of immunogen-encoding RNA
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013090648A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
PE15412018A1 (en) 2011-10-27 2018-09-26 Massachusetts Inst Technology Functionalized derivatives of amino acids in the n terminal capable of forming microspheres encapsulating drug
JP2013095755A (en) 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd Cationic lipid
RU2678807C2 (en) 2011-11-18 2019-02-01 Элнилэм Фармасьютикалз, Инк. Rnai agents, compositions and methods for use thereof for treating transthyretin (ttr) associated diseases
CA2858694A1 (en) 2011-12-12 2013-06-20 Kyowa Hakko Kirin Co., Ltd. Lipid nano particles comprising combination of cationic lipids
JP6182457B2 (en) 2011-12-12 2017-08-16 協和発酵キリン株式会社 Lipid nanoparticles for drug delivery comprising a cationic lipid
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
NZ700075A (en) 2012-02-24 2016-05-27 Protiva Biotherapeutics Inc Trialkyl cationic lipids and methods of use thereof
US9877919B2 (en) 2012-03-29 2018-01-30 Translate Bio, Inc. Lipid-derived neutral nanoparticles
US20150064235A1 (en) 2012-03-30 2015-03-05 Moderna Therapeutics, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US10245229B2 (en) 2012-06-08 2019-04-02 Translate Bio, Inc. Pulmonary delivery of mRNA to non-lung target cells
CA2875236A1 (en) 2012-06-22 2013-12-27 Julian I. Schroeder Compositions and methods for mediating plant stomatal development in response to carbon dioxide and applications for engineering drought tolerance in plants
JP6108197B2 (en) 2012-07-02 2017-04-05 日油株式会社 Method for producing a tertiary amino group-containing lipid
TW201726599A (en) 2012-07-06 2017-08-01 Kyowa Hakko Kirin Co Ltd Cationic lipid
CN104471062A (en) 2012-07-16 2015-03-25 协和发酵麒麟株式会社 Rnai pharmaceutical composition capable of suppressing expression of kras gene
EP2882706A1 (en) 2012-08-13 2015-06-17 Massachusetts Institute of Technology Amine-containing lipidoids and uses thereof
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US20150366997A1 (en) 2012-12-07 2015-12-24 Shire Human Genetics Therapies, Inc. COMPOSITIONS AND METHODS FOR mRNA DELIVERY
AU2014281031A1 (en) 2013-06-17 2016-01-21 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components
WO2014204728A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
EP3327127A1 (en) 2012-12-12 2018-05-30 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
CN104902925A (en) 2013-01-10 2015-09-09 诺华股份有限公司 Influenza virus immunogenic compositions and uses thereof
MX2015012865A (en) 2013-03-14 2016-07-21 Shire Human Genetic Therapies Methods for purification of messenger rna.
AU2014239184B2 (en) 2013-03-14 2018-11-08 Translate Bio, Inc. Methods and compositions for delivering mRNA coded antibodies
DK2968586T3 (en) 2013-03-14 2018-10-08 Translate Bio Inc CFTR mRNA compositions and related methods and uses
US20140288149A1 (en) 2013-03-15 2014-09-25 Graham Lord Mir-142 and antagonists thereof for treating disease
WO2014144196A1 (en) 2013-03-15 2014-09-18 Shire Human Genetic Therapies, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
CN105658800A (en) 2013-10-22 2016-06-08 夏尔人类遗传性治疗公司 CNS delivery of MRNA and uses thereof
JP2016535738A (en) 2013-10-22 2016-11-17 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド Lipid formulations for the delivery of messenger rna
AU2014340092A1 (en) 2013-10-22 2016-05-05 Translate Bio, Inc. mRNA therapy for Argininosuccinate Synthetase Deficiency
EA201690581A1 (en) 2013-10-22 2016-09-30 Шир Хьюман Дженетик Терапис, Инк. TREATMENT OF phenylketonuria C mRNA
EP3071696A2 (en) 2013-11-22 2016-09-28 Mina Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use
CA2932436A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
JP2017532001A (en) 2013-12-12 2017-11-02 ザ・ブロード・インスティテュート・インコーポレイテッド Systems for sequence manipulation by optimization CRISPR-Cas system, the methods and compositions
RU2016128077A3 (en) 2013-12-12 2018-12-06
AU2014361826A1 (en) 2013-12-12 2016-06-23 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using particle delivery components
US20170143848A1 (en) 2014-03-24 2017-05-25 Shire Human Genetic Therapies, Inc. Mrna therapy for the treatment of ocular diseases
CA2944800A1 (en) 2014-04-25 2015-10-29 Shire Human Genetic Therapies, Inc. Methods for purification of messenger rna
WO2015184256A2 (en) 2014-05-30 2015-12-03 Shire Human Genetic Therapies, Inc. Biodegradable lipids for delivery of nucleic acids
EP3153172A4 (en) 2014-06-04 2018-01-17 Kyowa Hakko Kirin Co., Ltd. Ckap5-gene-silencing rnai pharmaceutical composition
CN106795142A (en) 2014-06-24 2017-05-31 夏尔人类遗传性治疗公司 Stereochemically enriched compositions for delivery of nucleic acids
AU2015280499A1 (en) 2014-06-25 2017-02-09 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
AU2015283954A1 (en) 2014-07-02 2016-12-22 Translate Bio, Inc. Encapsulation of messenger RNA
CN107106874A (en) 2014-08-29 2017-08-29 阿尔尼拉姆医药品有限公司 Methods of treating transthyretin (ttr) mediated amyloidosis
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
EP3201338A1 (en) 2014-10-02 2017-08-09 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression
EP3226912A1 (en) 2014-12-05 2017-10-11 Rana Therapeutics Inc. Messenger rna therapy for treatment of articular disease
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
WO2016094867A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Protected guide rnas (pgrnas)
EP3230452A1 (en) 2014-12-12 2017-10-18 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
EP3234192A1 (en) 2014-12-19 2017-10-25 The Broad Institute Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
AU2015369725A1 (en) 2014-12-24 2017-06-29 Massachusetts Institute Of Technology CRISPR having or associated with destabilization domains
EP3270894A1 (en) 2015-03-19 2018-01-24 Translate Bio, Inc. Mrna therapy for pompe disease
WO2016197132A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Treating hepatitis b virus infection using crispr
WO2016205745A2 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
WO2016205764A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CA3012607A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
AU2016280893A1 (en) 2015-06-18 2018-01-18 Massachusetts Institute Of Technology CRISPR enzyme mutations reducing off-target effects
WO2016205691A1 (en) 2015-06-19 2016-12-22 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
AU2016285852A1 (en) 2015-06-29 2017-12-21 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20180208932A1 (en) 2015-07-29 2018-07-26 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis b virus gene expression
MX2018000981A (en) 2015-07-31 2018-06-11 Alnylam Pharmaceuticals Inc TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES.
US9856481B2 (en) 2015-08-13 2018-01-02 Ann & Robert H. Lurie Children's Hospital MicroRNA treatment of fibrosis
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP3362555A1 (en) 2015-10-14 2018-08-22 Translate Bio, Inc. Modification of rna-related enzymes for enhanced production
KR20180133374A (en) 2015-10-22 2018-12-14 더 브로드 인스티튜트, 인코퍼레이티드 Type vi-b crispr enzyme system and
WO2017074788A1 (en) 2015-10-27 2017-05-04 The Broad Institute Inc. Compositions and methods for targeting cancer-specific sequence variations
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2018081480A1 (en) 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
EP3368689A2 (en) 2015-10-28 2018-09-05 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
EP3368507A1 (en) 2015-10-28 2018-09-05 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017096326A1 (en) 2015-12-02 2017-06-08 Massachusetts Institute Of Technology Method for efficient generation of neurons from non-neuronal cells
JP2019504002A (en) 2015-12-10 2019-02-14 モデルナティーエックス, インコーポレイテッド Compositions and methods for the delivery of therapeutic agents
WO2017106657A1 (en) 2015-12-18 2017-06-22 The Broad Institute Inc. Novel crispr enzymes and systems
WO2017112865A1 (en) 2015-12-22 2017-06-29 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
WO2017111172A1 (en) 2015-12-25 2017-06-29 協和発酵キリン株式会社 Compounds as cationic lipids
WO2017177169A1 (en) 2016-04-08 2017-10-12 Rana Therapeutics, Inc. Multimeric coding nucleic acid and uses thereof
WO2017184786A1 (en) 2016-04-19 2017-10-26 The Broad Institute Inc. Cpf1 complexes with reduced indel activity
EP3445848A1 (en) 2016-04-19 2019-02-27 The Broad Institute, Inc. Novel crispr enzymes and systems
CA3026110A1 (en) 2016-04-19 2017-11-02 The Broad Institute, Inc. Novel crispr enzymes and systems
CA3027312A1 (en) 2016-06-13 2017-12-21 Translate Bio, Inc. Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
CA3028158A1 (en) 2016-06-17 2017-12-21 The Broad Institute, Inc. Type vi crispr orthologs and systems
WO2018005873A1 (en) 2016-06-29 2018-01-04 The Broad Institute Inc. Crispr-cas systems having destabilization domain
CA3034681A1 (en) 2016-06-30 2018-01-04 Arbutus Biopharma Corporation Compositions and methods for delivering messenger rna
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2018089846A1 (en) 2016-11-10 2018-05-17 Translate Bio, Inc. Subcutaneous delivery of messenger rna
US20180153822A1 (en) 2016-11-10 2018-06-07 Translate Bio, Inc. Process of Preparing mRNA-Loaded Lipid Nanoparticles
WO2018157154A2 (en) 2017-02-27 2018-08-30 Translate Bio, Inc. Novel codon-optimized cftr mrna
WO2018165257A1 (en) 2017-03-07 2018-09-13 Translate Bio, Inc. Polyanionic delivery of nucleic acids
US20180333457A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF CODON-OPTIMIZED mRNA ENCODING CFTR
WO2018232017A1 (en) 2017-06-13 2018-12-20 Flagship Pioneering, Inc. Compositions comprising curons and uses thereof
WO2018236849A1 (en) 2017-06-19 2018-12-27 Translate Bio, Inc. Messenger rna therapy for the treatment of friedreich's ataxia

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
EP0032578B1 (en) 1980-01-16 1984-07-25 Hans Georg Prof. Dr. Weder Process and dialysis-installation for the preparation of bilayer-vesicles and their use
US4598051A (en) 1980-03-12 1986-07-01 The Regents Of The University Of California Liposome conjugates and diagnostic methods therewith
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5550289A (en) 1985-01-07 1996-08-27 Syntex (U.S.A.) Inc. N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses therefor
US5320906A (en) 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
FR2645866B1 (en) 1989-04-17 1991-07-05 Centre Nat Rech Scient News lipopolyamines, their preparation and their use
JPH03126211A (en) 1989-10-12 1991-05-29 Nippon Chemicon Corp Electrolyte for electrolytic capacitor
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
JP2774417B2 (en) 1991-08-07 1998-07-09 株式会社ディ・ディ・エス研究所 Branched sugar complexes and particulate carrier having a peptide backbone
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6001644A (en) 1991-12-17 1999-12-14 The Regents Of The University Of California Mammalian transformation complex comprising a lipid carrier and DNA encoding CFTR
CA2130264A1 (en) 1992-02-19 1993-09-02 Harris Busch Oligonucleotide modulation of cell growth
US5811406A (en) 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
JP2854203B2 (en) 1992-09-03 1999-02-03 株式会社ディ・ディ・エス研究所 Process for the preparation of liposomes
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5674908A (en) * 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
FR2714830B1 (en) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa A composition containing nucleic acids, preparation and uses.
US6989434B1 (en) * 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US6075012A (en) * 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
JPH10506093A (en) 1994-06-22 1998-06-16 メガバイオス・コーポレイション Cationic amphiphilic compound
FR2722506B1 (en) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa A composition containing nucleic acids, preparation and uses
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
DE69527206D1 (en) 1994-09-30 2002-08-01 Inex Pharmaceuticals Corp Means to bring polyanionic materials in cells
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5627159A (en) * 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
AU701106B2 (en) * 1995-06-07 1999-01-21 Promega Biosciences, Inc. Novel carbamate-based cationic lipids
EP0874910A4 (en) * 1995-06-07 1999-04-21 Life Technologies Inc Peptide-enhanced cationic lipid transfections
WO1996040725A1 (en) * 1995-06-07 1996-12-19 Genta Incorporated Phosphonic acid-based cationic lipids
AU723163B2 (en) 1995-06-07 2000-08-17 Tekmira Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6339173B1 (en) * 1996-07-22 2002-01-15 Promega Biosciences, Inc. Amide-based cationic lipids
WO1997003939A1 (en) * 1995-07-21 1997-02-06 Genta Incorporated Novel amide-based cationic lipids
EP0863749A2 (en) * 1995-11-30 1998-09-16 Vical Incorporated Complex cationic lipids
US6330349B1 (en) * 1995-11-30 2001-12-11 Chromavision Medical Systems, Inc. Automated method for image analysis of residual protein
US5817856A (en) * 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
US6284267B1 (en) * 1996-08-14 2001-09-04 Nutrimed Biotech Amphiphilic materials and liposome formulations thereof
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US5877220A (en) * 1997-03-06 1999-03-02 Genta, Incorporated Amide-based oligomeric cationic lipids
US6034135A (en) * 1997-03-06 2000-03-07 Promega Biosciences, Inc. Dimeric cationic lipids
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
DE69841002D1 (en) 1997-05-14 2009-09-03 Univ British Columbia Highly efficient encapsulation of nucleic acids in lipid vesicles
WO1998051285A2 (en) 1997-05-15 1998-11-19 Genzyme Corporation Cationic amphiphile formulations
CA2792406A1 (en) 1997-10-10 1999-04-22 Tekmira Pharmaceuticals Corporation Methods for encapsulating nucleic acids in lipid bilayers
US6410328B1 (en) * 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
CA2271582A1 (en) 1998-05-14 1999-11-14 Sean C. Semple Method for administration of therapeutic agents, including antisense, with repeat dosing
AT237312T (en) 1998-07-20 2003-05-15 Protiva Biotherapeutics Inc In liposome-encapsulated nucleic acid complex
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
EP2298728A1 (en) * 1998-11-12 2011-03-23 Life Technologies Corporation Transfection reagents
US6649780B1 (en) * 1998-12-22 2003-11-18 Valentis, Inc. Cationic lipids
AU783647B2 (en) 1999-04-20 2005-11-17 University Of British Columbia, The Cationic peg-lipids and methods of use
US6696424B1 (en) * 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
US20010048940A1 (en) * 1999-06-18 2001-12-06 Jennifer D. Tousignant Cationic amphiphile micellar complexes
IL147564D0 (en) 1999-07-14 2002-08-14 Alza Corp Neutral lipopolymer and liposomal compositions containing same
EP1194122B1 (en) * 1999-07-15 2005-01-12 Inex Pharmaceuticals Corp. Methods for preparation of lipid-encapsulated therapeutic agents
AU785017B2 (en) 2000-01-10 2006-08-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
WO2002081628A2 (en) 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
WO2002034236A2 (en) 2000-10-25 2002-05-02 The University Of British Columbia Lipid formulations for target delivery
AU3238702A (en) * 2000-10-27 2002-05-06 Invitrogen Corp Method for introducing antisense oligonucleotides into eucaryotic cells
EP2348133B1 (en) 2000-12-01 2014-07-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US20040142892A1 (en) 2001-04-30 2004-07-22 The University Of British Columbia Autogene nucleic acids encoding a secretable RNA polymerase
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
JP4699025B2 (en) 2002-05-15 2011-06-08 サッター・ウエスト・ベイ・ホスピタルズSutter West Bay Hospitals Delivery of a nucleic-acid-like compound
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004065546A2 (en) 2003-01-16 2004-08-05 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ICAM-1
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
CA2528402A1 (en) 2003-06-18 2004-12-23 Yissum Research Development Company Of The Hebrew University Of Jerusale M Sphingoid polyalkylamine conjugates for vaccination
AU2004257373B2 (en) * 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
CA2551022C (en) * 2003-09-15 2013-06-04 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
CA2569645C (en) * 2004-06-07 2014-10-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
CA2572439A1 (en) * 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor
EP2380897B1 (en) 2004-09-24 2015-05-13 Alnylam Pharmaceuticals, Inc. RNAi modulation of ApoB and uses thereof
EP2199298A1 (en) 2004-11-17 2010-06-23 Protiva Biotherapeutics Inc. Sirna silencing of Apolipoprotein B
DE102004060863A1 (en) * 2004-12-17 2006-06-22 Dr. Johannes Heidenhain Gmbh Angle measuring device
US7514099B2 (en) * 2005-02-14 2009-04-07 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US20060228406A1 (en) * 2005-03-17 2006-10-12 Invitrogen Corporation Transfection reagent for non-adherent suspension cells
EP2770057A1 (en) * 2008-04-15 2014-08-27 Protiva Biotherapeutics Inc. Silencing of CSN5 gene expression using interfering RNA
WO2009129387A2 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof
WO2009132131A1 (en) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
CN105709229A (en) 2008-11-10 2016-06-29 阿尔尼拉姆医药品有限公司 Novel lipids and compositions for the delivery of therapeutics
US8569256B2 (en) * 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
EP2640700B1 (en) * 2010-11-15 2018-10-31 Life Technologies Corporation Amine-containing transfection reagents and methods for making and using same

Also Published As

Publication number Publication date
EP1766035A4 (en) 2009-04-22
CA2569664A1 (en) 2005-12-22
US9181545B2 (en) 2015-11-10
AU2005252273A1 (en) 2005-12-22
US20190071669A1 (en) 2019-03-07
AU2005252273B2 (en) 2011-04-28
US20060008910A1 (en) 2006-01-12
CA2569664C (en) 2013-07-16
EP1766035A1 (en) 2007-03-28
US7799565B2 (en) 2010-09-21
US9926560B2 (en) 2018-03-27
JP4796062B2 (en) 2011-10-19
US20110060032A1 (en) 2011-03-10
JP2008501730A (en) 2008-01-24
US20160115477A1 (en) 2016-04-28
WO2005121348A1 (en) 2005-12-22
EP1766035B1 (en) 2011-12-07

Similar Documents

Publication Publication Date Title
AT539708T (en) Wirbelfazettengelenkprothese
AT536418T (en) Lipidverkapselte interference-rna
AT543462T (en) Allo-implant
AT462363T (en) Polyaxialpedikelschraubenanordung
DE602005014923D1 (en) Teilchenbestrahlungssystem
AT415976T (en) Brombeerextrakt
AT381540T (en) Oximesther-photoinitiators
DE602005015457D1 (en) Ungselements
DE602004014644D1 (en) Teantrieb
DE602005011251D1 (en) Zettenvorrichtung
DE602004011270D1 (en) Auslasszusatzmodul
DE602005011516D1 (en) Nähfadenankereinführungssystem
AT415112T (en) Abschminkapplikator
AT360450T (en) Sicherheitsdauerverweilnadel
AT473021T (en) Nichtkräuselnde polyhydroxyalkanoatnähte
DE602004025621D1 (en) Stentreduziersystem
DE602005020742D1 (en) Sequenzamplifikations- and -nachweisverfahrens
DE602005019073D1 (en) Zenteseinstrument
AT538176T (en) Polymilchsäureharzzusammensetzung
AT371694T (en) Mq-t propylsiloxanharze
DE602004032477D1 (en) Ragglieds
AT535227T (en) Selbsterwärmendes rasierschaumprodukt
AT526869T (en) Hydratationsmonitor
DE602005016654D1 (en) Ltungssystem
DE602005013789D1 (en) -eingabeabtastung